Trusopt is used to treat open-angle glaucoma and other causes of high pressure inside the eye.
Trusopt is a carbonic anhydrase inhibitor formulated for topical ophthalmic use. Dorzolamide reduces the amount of fluid in the eye, which decreases pressure inside the eye.
To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap. Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will prevent your dispenser from operating properly. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and eye. Invert the bottle, and press lightly with the thumb or index finger over the “Finger Push Area” until a single drop is dispensed into the eye as directed by your doctor. DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP. The dose is one drop of Trusopt in the affected eye s three times daily. Trusopt may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. When Trusopt is used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye s , two times daily. If more than one ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures. Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. Trusopt contains the preservative benzalkonium chloride, which may cause eye irritation. Contact lenses should be removed prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.
Trusopt contains dorzolamide, a sulfonamide; and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of Trusopt. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
Possible side effect
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using dorzolamide ophthalmic and call your doctor at once if you have a serious side effect such as stomach pain, loss of appetite, dark urine, jaundice yellowing of the skin or eyes ; swelling or redness of your eyelids; eye redness, pain, discomfort, or sensitivity to light; drainage, crusting, or oozing of your eyes or eyelids; severe skin reaction: fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads especially in the face or upper body and causes blistering and peeling.
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and Trusopt. The concomitant administration of Trusopt and oral carbonic anhydrase inhibitors is not recommended. Specific drug interaction studies have not been performed with dorzolamide. In clinical studies, dorzolamide was used concomitantly with the following medications without evidence of adverse interactions: betaxolol ophthalmic solution and systemic medications, timolol ophthalmic solution, including ACE-inhibitors, diuretics, calcium-channel blockers, non-steroidal anti-inflammatory drugs including aspirin, and hormones e.g. oestrogen, insulin, thyroxine .
In case you have missed to take the prescribed dose of this drug, take it as soon as possible. If you are already supposed to take your next dose, do not take the dose you forgot and keep your ordinary dosage schedule. Avoid compensating a missed dose by taking an extra one.
Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride. Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels particularly potassium and blood pH levels should be monitored.
Store Trusopt at 15-30°C 59-86°F . Protect from light.
The information presented at the site has a general character. Note please this information cannot be used for self-treatment and self diagnosis. You should consult with your doctor or health care adviser regarding any specific instructions of your condition. The information is reliable, but we concede it could contain mistakes. We are not responsible for any direct, indirect, special or other damage caused by use of this information on the site and also for consequences of self-treatment.